Neuroblastoma: Therapy for infants with good prognosis
β Scribed by Nitschke, Ruprecht ;Humphrey, G. Bennett ;Sexauer, Charles L. ;Smith, E. Ide
- Book ID
- 102522470
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 367 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Therapy was designed to achieve a high cure rate and to prevent serious therapeutic side effects for 11 infants younger than one year old with neurobfastoma who had a favorable prognosis (Evans Stages I, ll, I l l , and IV-S). It consisted of surgery alone if the tumor was totally removed (one infant) and of surgery and low doses of cytoxan and vincristine for a period of 1 year if the tumor was incompletely removed (seven infants). In addition, radiation therapy was applied to u n r e sected dumbbell tumors (three infants). All infants are alive without evidence of disease with the exception of one who died in an accident. The follow-up time varies from 2-8 years. The drug combination prevented recur-rences in two infants whose tumor was reduced by surgery to less than 10% of the original size. In five infants, chemotherapy reduced the size of large residual tumor masses. Two of these masses were subsequently removed. The tumors of the three other infants recurred while on chemotherapy and were successfully eradicated by surgery or radiation therapy. Two infants were not treated according to this therapeutic plan. Although they had small residual masses after surgery, no chemotherapy was given. They are alive without recurrence of the disease 2 years or more after diagnosis. In summary, cure was achieved in these infants without intensive chemotherapy.
π SIMILAR VOLUMES
The Quebec Neuroblastoma Screening Project (QNSP) was initiated to determine whether mass screening would reduce mortality from this tumor in a large cohort of infants. A total of 476,603 children were born in the province of Quebec (PQ) from May 1, 1989 through April 30, 1994 and were eligible for